C4 Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop novel small-molecule medicines that harness the body's natural protein recycling system to eliminate disease-causing proteins. Founded in 2015 and headquartered in Watertown, Massachusetts, the company leverages its proprietary TORPEDO platform to design degrader therapies, including proteolysis-targeting chimeras (PROTACs), degradable molecular glues, and degrader-antibody conjugates, primarily targeting oncology indications such as multiple myeloma, non-Hodgkin's lymphoma, BRAF V600X-mutated solid tumors including melanoma and colorectal cancer, and non-small cell lung cancer with EGFR L858R mutations. Its pipeline features lead candidates cemsidomide, an oral IKZF1/3 degrader for relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma; CFT1946, a BRAF V600X degrader for solid tumors; and CFT8919, an EGFR L858R degrader licensed to Betta Pharmaceuticals for development in Greater China; alongside earlier-stage programs and discovery efforts in autoimmune diseases through partnerships. Recent developments include pricing a $125 million underwritten offering in October 2025 led by RA Capital Management to fund registrational Phase 2 and Phase 1b trials of cemsidomide, including a clinical trial collaboration with Pfizer for combination with elranatamab in multiple myeloma, with potential additional $225 million from warrants; announcing 2025 milestones such as cemsidomide data presentations, CFT1946 expansion cohorts, and CFT8919 dose escalation results; progress in Biogen collaboration with an IRAK4 degrader advancing to clinic; and discontinuation of certain wholly-owned pipeline elements like the BRAF program to prioritize cemsidomide amid a cash position of $267.3 million as of December 31, 2024, extending runway into 2027.
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
C4 Therapeutics to Participate in Upcoming Conferences
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 58.8% in March
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of “Moderate Buy” by Brokerages
C4 Therapeutics to Participate in Upcoming March Conferences